Interventional Cardiology Devices Market worth $42.39 billion by 2031
The report "Interventional Cardiology Devices Market by Type (Angioplasty Stent, Catheter, Guidewire, Atherectomy, Drug Eluting/Cutting Balloon, IVUS/OCT, Vascular Closure Device, Plaque Modification Device, Hemodynamic Alteration Devices) - Global Forecast to 2031" is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a CAGR of 6.4%.
Browse 380 market data Tables and 80 Figures spread through 400 Pages and in-depth TOC on "Interventional Cardiology Devices Market, by Type (Angioplasty Stent, Catheter, Guidewire, Atherectomy, Drug Eluting/Cutting Balloon, IVUS/OCT, Vascular Closure Device, Plaque Modification Device, Hemodynamic Alteration Devices) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/minimally-invasive-interventional-cardiology-devices-market-548.html
The market is gaining momentum as the rising prevalence of cardiovascular diseases, including coronary artery disease and structural heart disorders, combines with a strong clinical shift from open-heart surgery toward minimally invasive, catheter-based interventions. Shorter hospital stays, faster recovery, and lower complication rates are accelerating device adoption across hospitals and outpatient settings. Rapid technological advancement—next-generation drug-eluting stents, bioresorbable scaffolds, transcatheter heart valves, intravascular imaging (IVUS/OCT), and physiology-guided diagnostics—is improving procedural accuracy and expanding treatable indications. Leading manufacturers, including Boston Scientific, Medtronic, Abbott, and Edwards Lifesciences, are investing heavily in R&D, clinical evidence, and emerging-market expansion to strengthen their positions.
By type of angioplasty stent, the drug-eluting stents segment is expected to register the highest CAGR during the forecast period.
The drug-eluting stents (DES) segment is expected to grow fastest within the angioplasty stents market during the forecast period. Growth is driven by the persistent burden of coronary artery disease and a strong clinical preference for percutaneous coronary intervention (PCI) over surgical revascularization in suitable patients. DES have a well-established ability to reduce restenosis and the need for repeat revascularization compared with bare-metal stents, supporting their continued use as the standard of care in most coronary interventions. Technological advances—thinner strut designs, improved polymer and bioresorbable coatings, and enhanced drug formulations—continue to improve safety profiles and long-term outcomes, extending DES use into complex and high-risk lesions.
By end user, the hospitals segment is estimated to hold the largest market share during the forecast period.
The hospitals segment is estimated to dominate the interventional cardiology devices market in 2025. Hospitals perform the majority of diagnostic angiography and complex coronary and structural heart interventions, supported by established catheterization-lab infrastructure, specialized interventional teams, and the imaging and hemodynamic monitoring required for high-risk cases. Rising procedure volumes, an aging population with multiple comorbidities, and continued investment in advanced cath-lab capabilities reinforce the segment's leading position. Ambulatory surgery centers represent the second-largest end user, supported by the shift of selected low- to moderate-risk procedures toward cost-effective, same-day outpatient care.
North America is expected to lead the market during the forecast period.
North America holds the largest share of the interventional cardiology devices market, supported by a high prevalence of cardiovascular disease, advanced cath-lab infrastructure, favorable reimbursement, rapid adoption of new technologies, and the presence of leading manufacturers with strong R&D pipelines. The US alone accounts for a substantial portion of global demand, with rising volumes of complex coronary and structural heart interventions and growing adoption of AI-powered imaging and navigation tools. Asia Pacific is expected to register strong growth, driven by expanding catheterization-lab capacity, increasing healthcare investment, and improving access to advanced cardiac care across China, Japan, and India.
The major players in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd. (Singapore), and Asahi Intecc Co., Ltd. (Japan).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Interventional Cardiology Devices Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
